medcelerator · clinician one-pager

New Treatment for Immune-Related Anemia in Teens and Adults

Imaavy (nipocalimab-aahu) — neonatal Fc receptor blocker for warm autoimmune hemolytic anemia in adults and adolescents 12 years and older after corticosteroid exposure

FDA Approved · United States · September 11, 2026

Condition: Warm Autoimmune Hemolytic Anemia

Who this is for

This is for people 12 years and older with warm autoimmune hemolytic anemia who are currently on or have previously received corticosteroids and who may be candidates for labelled US Imaavy monthly IV infusions. It explains the first FDA-approved wAIHA pathway, how the 30 mg/kg every-4-weeks schedule differs from the gMG dose, the durable hemoglobin numbers from NCT04119050, infection / hypersensitivity / infusion-reaction watchpoints, and how to talk with a hematology clinician — without treating a Canadian or EU gMG label, a DIY import, or pivotal-trial follow-up as the wAIHA care plan. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-warm-autoimmune-hemolytic-anemia

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/imaavy-nipocalimab-waiha